Intrathoracic extensive-stage small cell lung cancer: assessment of the benefit of thoracic and brain radiotherapy using the SEER database

Background Extensive-stage small cell lung cancer (ESCLC) includes metastatic disease and locally advanced disease confined to the thorax that cannot be encompassed in a typical radiation portal. We assessed and then compared the benefits of thoracic radiotherapy (TRT) and/or brain radiotherapy (BRT...

Full description

Saved in:
Bibliographic Details
Published in:International journal of clinical oncology 2016-12, Vol.21 (6), p.1062-1070
Main Authors: Mahmoud, Omar, Kwon, Deukwoo, Greenfield, Brad, Wright, Jean L., Samuels, Michael A.
Format: Article
Language:English
Subjects:
Aged
Brain Neoplasms - mortality
Brain Neoplasms - radiotherapy
Brain Neoplasms - secondary
Cancer Research
Female
Humans
Kaplan-Meier Estimate
Lung cancer
Lung Neoplasms - mortality
Lung Neoplasms - pathology
Lung Neoplasms - radiotherapy
Male
Medicine
Medicine & Public Health
Middle Aged
Neoplasm Metastasis
Neoplasm Staging
Oncology
Original Article
Outcome and Process Assessment (Health Care)
Prognosis
Prospective Studies
Radiation therapy
Radiotherapy - methods
Retrospective Studies
SEER Program - statistics & numerical data
Small Cell Lung Carcinoma - mortality
Small Cell Lung Carcinoma - pathology
Small Cell Lung Carcinoma - radiotherapy
Surgical Oncology
United States - epidemiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Extensive-stage small cell lung cancer (ESCLC) includes metastatic disease and locally advanced disease confined to the thorax that cannot be encompassed in a typical radiation portal. We assessed and then compared the benefits of thoracic radiotherapy (TRT) and/or brain radiotherapy (BRT) on overall survival (OS) between the intrathoracic (T-ESCLC) and metastatic (M-ESCLC) groups using the Surveillance Epidemiology and End Results database. Methods TRT and BRT data were available for 10150 patients treated from 1988−1997. The T-ESCLC group included 1774 patients. The Kaplan–Meier method was used to estimate OS and the proportional hazards model was used to estimate OS hazard ratios for prognostic factors including age, gender, race, tumor size, T/N stage, TRT, and BRT. Results The 2-year OS for T-ESCLC was 7.8 % compared to 3 % in the M-ESCLC group ( p  
ISSN:1341-9625
1437-7772
DOI:10.1007/s10147-016-1011-z